Eğitim

Yan Dal Uzmanlık - Bakirkoy Dr Sadi Konuk Eğitim ve Araştırma Hastanesi
Medikal Onkoloji Yan Dal Asistanı 2016-2019

Ana Dal Uzmanlık - Istanbul Eğitim ve Araştırma Hastanesi
İç Hastalıkları Asistanı 2011–2015

Üniversite - Trakya Üniversitesi
Tıp Fakültesi 2004-2010

Deneyim

2024- Devam Ediyor - İstanbul Onkoloji Hastanesi
Tıbbi Onkoloji Uzmanı

 

2019 – 2023 - Istanbul Ümraniye Eğitim ve Araştırma Hastanesi
Tıbbi Onkoloji Uzmanı

 

2019 – 2019 - Adıyaman Eğitim ve Araştırma Hastanesi
Tıbbi Onkoloji Uzmanı

 

2016 – 2019 - Bakırköy Dr Sadi Konuk Eğitim ve Araştırma Hastanesi
Medikal Onkoloji Yan Dal Asistanı

2016 – 2016 - Istanbul Semiha Şakir KDÇ Hastanesi
İç Hastalıkları Uzmanı
 

2015 – 2016 - Ağrı Devlet Hastanesi
İç Hastalıkları Uzmanı

2011 – 2015-Istanbul Eğitim ve Araştırma Hastanesi
İç Hastalıkları Asistanı

 

2010 – 2011 - Tekirdağ Şarköy Toplum Sağlığı Merkezi
Pratisyen Doktor

 

 

Eğitimler/Sertifikalar

• European Society of Medical Oncology Board Sertifikası (2022)
• Türk Tıbbi Onkoloji Derneği Yeterlilik Sertifikası (2019)
• Harvard Medical School HMX Pro Genetics-Cancer Genomics and Precision Oncology Certificate of Achievement (2023)
• Harvard Medical School HMX Pro Drug Development Certificate of Achievement(2023)

Türk Tıbbi Onkoloji Derneği

European Society of Medical Oncology

American Society of Clinical Oncology

İngilizce

Yayınlar

1. Efficacy and Safety of Trastuzumab Emtansine in older patients with HER2-positive advanced breast cancer: A real-world study. Cil I, Kucukarda A, Atci MM et al. Tumori Journal. 2022;108(1):19-25.
 

2. Prognostic Factors in Resected Biliary Tract Cancers and the Impact of Cytokeratin 20 Expression. Cil I, Oyman A, Isik S, Ayhan M, Okten IN, Yilmaz M, Ozcelik M. J Oncol Sci, 2021;7(3):125-132.
 

3. Hypothyroidism with sunitinib therapy and its correlation with survival outcomes in advanced renal cell carcinoma patients. Cil I, Karaca M, Zirtiloglu A, Yilmaz M, Dulgar O, Tural D. EJMI 2022;6(2):359–366.
 

4. Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c-MET Amplification. Cil I, Zirtiloglu A, Saydam N, Tural D. J BUON. Jan-Feb 2017;22(1):279-280.
 

5. What is the optimal treatment of metastatic hepatocellular carcinoma after complete resection; case presentation of ovarian metastasis. Cil I, Zirtiloglu A, Velibeyoglu MF, Tural D. J BUON. Mar-Apr 2017;22(2):557-558.
 

6. Long-lasting response with polycythemia to third-line axitinib treatment in metastatic renal cell carcinoma: Very rare case presentation. Dulgar O, Cil I, Zirtiloglu A, Tural D. J Oncol Pharm Pract. 2019 Sep;25(6):1512-1515.
 

7. An advanced c-MET-amplified NSCLC patient that was treated with crizotinib. Yilmaz M, Mese SG, Cil I, Zirtiloglu A. J Oncol Pharm Pract. 2020 Mar;26(2):474-477.
 

8. What are the optimal treatment modalities according to age group in gastric cancer patients? Zirtiloglu A, Cil I, Velibeyoglu MF, Tural D. J BUON. Mar-Apr 2017;22(2):312-319.
 

9. Does EGFR targeted therapy change the natural history of EGFR mutant status? Zirtiloglu A, Cil I, Tural D. J BUON. Mar-Apr 2017;22(2):560-561.
 

10. Hepatitis B Reactivation Rate Is Higher Undergoing Some Cytotoxic Chemotherapy in Patients with Solid Tumors. Karaca M, Tural D, Akar E, Cil I, Bayrak S, Ozet G, Yucel OK, Hocaoglu E, Ozet A. Chemotherapy. 2018;63(5):247-252.
 

11. Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy? Bozkaya Y, Köstek O, Sakin A, Özyükseler DT, Şakalar T, Çil İ. Support Care Cancer. 2020 May;28(5):2273-2282.
 

12. Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience. Ekenel M, Karabulut S, Cil I, Zirtiloglu A, Aydın E, Tural D. Actas Urol Esp (Engl Ed). 2020 Jan-Feb;44(1):27-33.
 

13. Determining the Current Situation of Geriatric Oncology in Turkey: A Survey of Medical Oncologists. Akagunduz B, Guven DC, Atci MM, Cil I, Karaçin C, Ozer M, Kilickap S. J Oncol Sci. 2021;7(1):25-30.
 

14. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313.
 

15. Evaluation of LIPI and mGPS as prognostic factors in extensive-stage small-cell lung cancer. Oyman A, Cil I, Ozcelik M, Ozyukseler DT, Basak M, Gokyer A, Okten IN. J Surg Med. 2022;6(2):115-119.
 

16. The effect of preoperative prognostic nutritional index on outcome in glioblastoma multiforme patients. Oyman A, Isik S, Eroz S, Ozcelik M, Cil I, Alan O, Basak M. J Surg Med. 2022;6(2):177–180.
 

17. Everolimus-Induced Oral Mucositis Can be Prevented by Hippophae Rhamnoides Extract in Rats. Akagunduz B, Ozer M, Cil I et al. EJMI 2021;5(1):81–88.
 

18. Effect of Adjuvant Chemotherapy in Stage III Cervical Cancer Patients Treated with Concurrent Chemoradiation: A Multicenter Study. Atci MM, Akagunduz B, Demir M, Dönmez Yilmaz B, Akin Telli T, Can O, Cil I, Goktas Aydın S, Ozyurt N, Onder AH, Selvi O, Sakin A. Oncol Res Treat. 2022;45(5):254-261.
 

19. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. J Chemother. 2022 Feb 17:1-10.
 

20. Impact of Diabetes on Clinical Outcomes of Prostate Cancer. Ozcelik M, Yaprak G, Gemici C, Oyman A, Cil I, Ozcelik S. EJMA. 2022;2(3):100-104.
 

21. Impact of Breast Cancer Subtypes on Pathological Complete Response Following Neoadjuvant Chemotherapy. Oyman A, Ozcelik M, Cil I. EJMI 2022;6(2):147–150.
 

22. Psychological impacts of COVID-19 pandemic in cancer patients on active treatment. Koca S, Koca E, Okten IN, Orengul F, Ozturk A, Ozcelik M, Oyman A, Cil I, Gumus M. Heliyon 2022 Aug;8(8):e10142.
 

23. Where Should Enzalutamide Be in The Metastatic Castration Resistant Prostate Cancer (mCRPC): A Multi-center Study. Koca S, Okten IN, Besiroglu M, Akin Telli T, Demirci A, Karaagac M, Cil I et al. EJMO 2023;7(1):34–41.
 

24. Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer. Gulturk I, Erdal GS, Sonmezoz GB, Yilmaz M, Tacar SY, Ozmen A, Ozyukseler DT, Dulgar O, Cil I, Tural D. İstanbul Med J 2022;23(4):269-274.
 

25. Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib. Olmez OF, Bilici A, Gursoy P, Cubukcu E, Sakin A, Korkmaz T, Cil I, Cakar B, Menekse S, Demir T, Acikgoz O, Hamdard J. Pulmonology. 2023;29(6):478-485.
 

26. Major and minor salivary gland cancers: A multicenter retrospective study. Hacioglu MB, Erdogan B, Cil I et al. Head Neck. 2023 Jul;45(7):1643-1653.

---

Kitap

1. İmmunoterapilerin Yan Etki Yönetimi. Bölüm Adı: İmmunoterapi ilişkili endokrin yan etkilerin yönetimi. Ömer Fatih ÖLMEZ, İbrahim ÇİL. Türkiye Klinikleri, 2019. Editör: İrfan ÇİÇİN ISBN: 978-625-401-602-8.
 

2. Temel Onkoloji. Bölüm Adı: Kök Hücre Biyolojisi ve Kanser Tedavisindeki Kullanım Alanları. İbrahim ÇİL. Akademisyen Yayınevi, 2020. Editör: Ali Murat SEDEF ISBN: 978-625-727-518-7.
 

3. Geriatrik Onkoloji. Bölüm Adı: Geriatrik Onkoloji Hastalarında Hedefe Yönelik Ajanların Kullanımı. İbrahim ÇİL. Akademisyen Yayınevi, 2021

. Editör: Ali Murat SEDEF, Baran AKAGÜNDÜZ ISBN: 978-625-7679-4.

---

Uluslararası Bilimsel Toplantılarda Sunulan Bildiriler

1. Hepatitis B and C reactivation rates due to cytotoxic chemotherapy in patients with solid tumors. Karaca M, Tural D, Cil I, Ozet G, Yucel OK, Ozet A. ESMO 2017 Congress.
 

2. Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: Two Turkish hospital experience, a retrospective comparative case series study. Ekenel M, Aydin E, Cil I, Zirtiloglu A, Tural D, Karabulut S. ESMO 2017 Congress.
 

3. Prognostic significance of PD-L1 in Stage II/III Non-Small Cell Lung Cancer. Deniz Tural, Mustafa Karaca, Emre Akar, Damla Okay, Ibrahim Cil, Nalan Akyurek, Aytug Uner, Ahmet Ozet. 2018 ASCO Annual Meeting.
 

4. Are Pretreatment Inflammation-Based Prognostic Scores Useful in Predicting the Outcomes of Patients with ALK-Positive NSCLC? Olmez OF, Bilici A, Gursoy P, Cubukcu E, Yildiz O, Sakin A, Korkmaz T, Cil I, Cakar B, Menekse S, Demir T, Acikgoz O, Hamdard J. IASLC 2019 World Conference on Lung Cancer.
 

5. Systemic Inflammatory Markers as Predictors of Response to Crizotinib in Patients with ALK-Positive Non-Small Cell Lung Cancer. Bilici A, Olmez OF, Gursoy P, Cubukcu E, Yildiz O, Sakin A, Korkmaz T, Cil I, Cakar B, Menekse S, Demir T, Acikgoz O, Hamdard J. IASLC 2019 World Conference on Lung Cancer.

---

Klinik Araştırmalar

1. A Phase III, open label, multicenter trial of avelumab versus platinum-based doublet as a first-line treatment of recurrent Stage IV PD-L1+ non-small cell lung cancer.
 

2. A Study of Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in participants with advanced urothelial cancer and selected fibroblast growth factor receptor gene aberrations.
 

3. A study of niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone for treatment of participants with metastatic prostate cancer.
 

4. A comparative study of BAT1706 and EU Avastin in patients with advanced non-squamous non-small cell lung cancer.